California-based late-stage biotech company Alume Biosciences announced on Friday that it has named Rick Gonzalez as its new chief commercial officer.
Gonzalez has more than three decades of experience in the pharmaceutical industry, serving in senior roles that involved significant global responsibilities. He led the development and implementation of globalisation and commercialisation strategies across Europe, Asia, the Middle East and Latin America at Spectrum Pharmaceuticals. He has expertise in specialty markets including Surgery, HIV/AIDS, Hematology and Oncology, with a comprehensive background in sales, marketing, operations, distribution, managed markets and government affairs. Gonzalez has also worked in key roles at companies such as Abraxis Oncology, Genzyme, Ligand Pharmaceuticals, Roche Laboratories and GlaxoSmithKline.
Dr Quyen Nguyen, Alume Biosciences CEO, said: "Alume is thrilled to welcome Rick Gonzalez as our new chief commercial officer. Rick's profound global commercial, operational and leadership experience, particularly in surgery, biotechnology, radiopharmaceuticals and medical devices, is directly aligned with our strategic objectives. His proven track record in product commercialisation will be instrumental as we advance ALM-488 towards a successful market introduction."
Alume Biosciences names new chief commercial officer
Senhwa Biosciences' Silmitasertib gains rare paediatric disease designation for Neuroblastoma
Sanofi, RadioMedix and Orano Med partner on rare cancer treatment
NeoGenomics to present breakthrough data at ESMO 2024 on ctDNA and NGS for cancer diagnostics
Pheon Therapeutics names new independent, non-executive director
Solu Therapeutics names new chief medical officer
Tyra Biosciences names new chief medical officer
Carisma and Moderna expand collaboration
OSE Immunotherapeutics initiates Phase 3 trial for cancer vaccine Tedopi
Phanes Therapeutics doses first subject in clinical study of PT886 in combination with chemotherapy
AbbVie advances solid tumour pipeline with new data at ESMO 2024
Amgen showcases promising data for IMDELLTRA in small cell lung cancer at WCLC 2024
Cantargia reports promising data for nadunolimab in cancer treatment